Genfit S.A. to Post FY2024 Earnings of $0.65 Per Share, Leerink Partnrs Forecasts (NASDAQ:GNFT)

Genfit S.A. (NASDAQ:GNFT - Free Report) - Stock analysts at Leerink Partnrs boosted their FY2024 EPS estimates for shares of Genfit in a research report issued on Thursday, September 19th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of $0.65 per share for the year, up from their previous estimate of $0.52. The consensus estimate for Genfit's current full-year earnings is $0.56 per share.

Separately, HC Wainwright restated a "buy" rating and set a $13.00 target price on shares of Genfit in a report on Friday.

Genfit Stock Up 3.1 %

Shares of NASDAQ:GNFT traded up $0.15 during midday trading on Monday, hitting $4.99. The company had a trading volume of 58,512 shares, compared to its average volume of 16,797. The firm has a fifty day simple moving average of $4.23 and a 200 day simple moving average of $4.06. The company has a quick ratio of 2.94, a current ratio of 2.94 and a debt-to-equity ratio of 0.92. Genfit has a 12 month low of $2.89 and a 12 month high of $6.05.

Hedge Funds Weigh In On Genfit

An institutional investor recently raised its position in Genfit stock. Optiver Holding B.V. increased its holdings in shares of Genfit S.A. (NASDAQ:GNFT - Free Report) by 2,229.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 82,359 shares of the company's stock after purchasing an additional 78,823 shares during the quarter. Optiver Holding B.V. owned 0.17% of Genfit worth $315,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 2.24% of the company's stock.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.